Proteomic analysis of retinopathy-related plasma biomarkers in diabetic patients

Diabetic retinopathy occurs in approximately 25% of patients with type 1 or type 2 diabetes; the disease can cause poor vision and even blindness because high glucose levels weaken retinal capillaries, causing leakage of blood into surrounding areas. We adopted a proteomics-based approach using 2D-DIGE and MALDI-TOF/TOF MS to compare the differential plasma proteome between diabetic retinopathy with significant retinopathy occurrence within 5 years after diagnosis of diabetes, and diabetic non-retinopathy without diagnosed retinopathy for more than 10 years after diagnosis of diabetes. We identified 77 plasma proteins, which represent 28 unique gene products. These proteins mainly have inflammatory response and coagulation roles. Our approach identified several potential diabetic retinopathy biomarkers including afamin and the protein arginine N-methyltransferase 5, which may be associated with the progression and development of diabetes. In conclusion, we report a comprehensive patient-based plasma proteomic approach to the identification of potential plasma biomarkers for diabetic retinopathy screening and detection.

Figure optionsDownload high-quality image (126 K)Download as PowerPoint slideHighlights
► Retinopathy occurs in approximately 25% of patients with type 1 or type 2 diabetes.
► 2D-DIGE and MALDI-TOF MS were used to analyze retinopathy markers.
► Numerous identified proteins that are associated with the progression of diabetic retinopathy.
► These identified proteins have roles in the inflammatory response and in coagulation.